A Non-Randomized, Open Label, One Treatment, One Group Study to Investigate the Intrapulmonary Lung Penetration of RO7079901 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
Price : $35 *
At a glance
- Drugs Meropenem (Primary) ; Nacubactam (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Roche
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 17 Aug 2017 New trial record
- 14 Aug 2017 Status changed from recruiting to active, no longer recruiting.